Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery (MIDAS)

This study has been completed.
Sponsor:
Collaborator:
Ethicon Endo-Surgery
Information provided by:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00488423
First received: June 18, 2007
Last updated: June 21, 2011
Last verified: June 2011

June 18, 2007
June 21, 2011
November 2006
November 2008   (final data collection date for primary outcome measure)
To assess the effect of gastric by-pass surgery to decrease lipotoxicity. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
To assess the effect of gastric by-pass surgery to decrease lipotoxicity. [ Time Frame: One year ]
Complete list of historical versions of study NCT00488423 on ClinicalTrials.gov Archive Site
To examine the effect of roux-en-Y compared to gastric banding on pancreatic B cell recovery or insulin secretion in response to oral and IV glucose. [ Time Frame: One Year ] [ Designated as safety issue: Yes ]
To examine the effect of roux-en-Y compared to gastric banding on pancreatic B cell recovery or insulin secretion in response to oral and IV glucose. [ Time Frame: One Year ]
Not Provided
Not Provided
 
Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery
Glucose Metabolism in the Immediate and Short Term Follow up From Bariatric Surgery

MIDAS involves an assessment of glucose levels obtained before and after bariatric surgery. There are two different procedural tests involved; an oral glucose tolerance test (mixed meal) and a hyperglycemic clamp test. Two tests are performed preoperatively and five more are performed postoperatively for a one year period. The associated labwork drawn with the mixed meal and clamp tests are demonstrating changes in glucose, insulin and gut hormone levels.

Tests performed are the Mixed Meal tolerance test, the Hyperglycemic Clamp test, c-peptide, free fatty acids, adipocyte hormone profile levels.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
  • Diabetes
  • Gastric Bypass
Procedure: Mixed Meal Tolerance test, Hyperglycemic clamp
Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
Other Name: MMTT
  • Active Comparator: Lap-band
    Patient undergoing Lap-band Bariatric Surgery
    Intervention: Procedure: Mixed Meal Tolerance test, Hyperglycemic clamp
  • Active Comparator: Gastric Bypass
    Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
    Intervention: Procedure: Mixed Meal Tolerance test, Hyperglycemic clamp
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Negative pregnancy test if female
  • ADA criteria for diabetes type II
  • Hematocrit > 35 creatinine < 1.9, AST < 3X upper limit of normal, ALT < 3X upper limit of normal, alkaline phos <3X upper limit of normal
  • Eligibility for bariatric surgery based on the NIH and clinical criteria
  • Mentally and legally capable of providing consent

Exclusion Criteria:

  • Lactating females
  • Must not have type I diabetes
  • Systemic steroids taken within 6 months
  • Clinically significant heart disease
  • Recent pulmonary embolism, untreated proliferative retinopathy, renal failure, uncontrolled hypertension, autonomic neuropathy, resting heart rate > 100, neuromuscular or musculoskeletal disease.
Both
19 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00488423
8585
No
Cleveland Clinic Foundation, Endocrine & Metabolic Institute Research
The Cleveland Clinic
Ethicon Endo-Surgery
Principal Investigator: Sangeeta R. Kashyap, MD The Cleveland Clinic
Principal Investigator: Philip R. Schauer, M.D. The Cleveland Clinic
The Cleveland Clinic
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP